Draft WHO pandemic deal pushes for equity to avoid COVID 'failure'
repeat
Send a link to a friend
[February 02, 2023]
By Jennifer Rigby and Gabrielle Tétrault-Farber
LONDON/GENEVA (Reuters) -Governments may have to reserve drugs and
vaccines for the World Health Organization to distribute in poorer
countries to avoid a repeat of the "catastrophic failure" during the
COVID-19 pandemic, according to an early draft of a global pandemic
agreement.
One of the most concrete proposals in the draft accord reviewed by
Reuters on Wednesday includes a measure to reserve 20% of any tests,
vaccines or treatments developed for use in poorer countries.
The draft also looks set to continue a long-running argument by calling
for intellectual property rights to be waived during pandemics, which
advocates say would allow for wider access to life-saving drugs and
vaccines more quickly.
The pharmaceutical industry is against the move.
The draft also retains earlier provisions that could see pharmaceutical
companies made to release details of any public contracts for vaccines
and treatments during such global health emergencies.
The agreement, which is commonly known as the pandemic treaty, has been
drawn up by WHO member states and will now go through a lengthy
negotiating process before being finalized.
Talks on the draft treaty will begin on Feb. 27 and are set to continue
to 2024. Member states have agreed that the treaty will be legally
binding for those who sign up, but it is not yet clear how that will be
enforced.
The draft was released to member states and non-governmental
organisations (NGOs) on Wednesday. It contains a number of measures to
ensure the world's response to the next pandemic is not only more
robust, but more equitable.
"It is a once-in-a-generation chance to make a paradigm shift in the
protection and improvement of the health of the world's people," WHO
spokesperson Fadela Chaib said of the accord.
The draft begins by saying it is being drawn up "in recognition of the
catastrophic failure of the international community in showing
solidarity and equity in response to the coronavirus disease (COVID-19)
pandemic".
[to top of second column]
|
Dr. Mayank Amin draws the Moderna
coronavirus disease (COVID-19) booster vaccine targeting BA.4 and
BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville,
Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
However, there will be "heat and
opposition" in the negotiations ahead, particularly around the
intellectual property provisions, said James Love, director of the
NGO Knowledge Ecology International.
"The 'accord' should build on the private sector's
strengths for innovative R&D, quick manufacturing scaling up and
distribution, which is built on a robust intellectual property
system," said Thomas Cueni, director general of the International
Federation of Pharmaceutical Manufacturers and Associations.
The draft also calls for a new WHO Global Pandemic Supply Chain and
Logistics Network to ensure better and fairer distribution of
counter-measures, as well as a global compensation scheme for
vaccine injuries.
It also proposes the WHO Pathogen Access and Benefit-Sharing System,
which urges countries to share pathogens and genomic sequences
"within hours".
Diagnostics, treatments and vaccines developed from the data should
be shared fairly, including a provision that the WHO gets 20% of any
production - 10% as donation and the rest at affordable prices - for
use in developing countries, the document suggests.
The plan aims to avoid countries sharing data on outbreaks not
getting access to counter-measures developed using the data.
"The provisions on transparency and equity are impressive," Love
said, "but I think negotiators need to do more work on how to create
incentives for governments and others to both invest and share
technologies".
(Reporting by Jennifer Rigby and Gabrielle Tétrault-Farber; Editing
by Josephine Mason, Arun Koyyur and Bill Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |